3D Medicines, Inc.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: HKG:1244
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 520 out of 844
Universe
Global Universe 11409 out of 14915
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
3D Medicines, Inc. |
32.4
High
|
520 out of 844 |
Inozyme Pharma, Inc. |
33.1
High
|
559 out of 844 |
Tenaya Therapeutics, Inc. |
34.3
High
|
616 out of 844 |
IGM Biosciences, Inc. |
39
High
|
787 out of 844 |
ENZYCHEM LIFESCIENCES Corp. |
44.2
Severe
|
840 out of 844 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
3D Medicines, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
3D Medicines, Inc.'s Management of ESG Material Risk is Average